



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



## Erlotinib (hydrochloride)

Item No. 35517

**CAS Registry No.:** 183319-69-9  
**Formal Name:** N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, monohydrochloride  
**Synonyms:** CP 358,774, NSC 718781, OSI-774  
**MF:** C<sub>22</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub> • HCl  
**FW:** 429.9  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 222, 246, 345 nm  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Erlotinib (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the erlotinib (hydrochloride) in the solvent of choice, which should be purged with an inert gas. Erlotinib (hydrochloride) is soluble in the organic solvent DMSO.

### Description

Erlotinib is an EGFR inhibitor ( $K_i = 2.7$  nM).<sup>1</sup> It is greater than 1,000-fold selective for EGFR over Src and Abl at 0.1  $\mu$ M.<sup>2</sup> Erlotinib induces caspase-3 and -7 activity in NCI H358 non-small cell lung cancer (NSCLC) cells when used at a concentration of 1  $\mu$ M.<sup>3</sup> Erlotinib (25 mg/kg) reduces EGF-induced EGFR autophosphorylation in an HN-5 head and neck cancer mouse xenograft model.<sup>2</sup> Formulations containing erlotinib have been used in the treatment of various cancers.

### References

1. Ciardiello, F. and Tortora, G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. *Clin. Cancer Res.* **7(10)**, 2958-2970 (2001).
2. Moyer, J.D., Barbacci, E.G., Iwata, K.K., *et al.* Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. *Cancer Res.* **57(21)**, 4838-4848 (1997).
3. Herbst, R.S. and Bunn, P.A., Jr. Targeting the epidermal growth factor receptor in non-small cell lung cancer. *Clin. Cancer Res.* **9(16)**, 5813-5824 (2003).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/20/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM